CSL Debt/Equity Ratio 2017-2024 | CSLLY

CSL debt/equity ratio for the quarter ending June 30, 2024 was 0.58.

  • CSL average debt/equity ratio for 2023 was 0.6, a 25% decline from 2022.
  • CSL average debt/equity ratio for 2022 was 0.48, a 5.88% increase from 2021.
  • CSL average debt/equity ratio for 2021 was 0.51, a 36.25% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

CSL Debt/Equity Ratio 2017-2024 | CSLLY

  • CSL average debt/equity ratio for 2023 was 0.6, a 25% decline from 2022.
  • CSL average debt/equity ratio for 2022 was 0.48, a 5.88% increase from 2021.
  • CSL average debt/equity ratio for 2021 was 0.51, a 36.25% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$150.5B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$115.4B
Gilead Sciences (GILD)$109.4B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$34.4B
Alnylam Pharmaceuticals (ALNY)$30.2B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$22.6B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18.3B
Moderna (MRNA)$14.3B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.6B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.8B
Vaxcyte (PCVX)$10.9B
Bio-Techne Corp (TECH)$10.5B
Sarepta Therapeutics (SRPT)$10.2B
Exact Sciences (EXAS)$10B
Exelixis (EXEL)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
QIAGEN (QGEN)$9.3B
Intra-Cellular Therapies (ITCI)$8.8B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$7.5B
Repligen (RGEN)$7.2B
Legend Biotech (LEGN)$7B